News - 25 Feb `23Newsletter: A Green Light For Vitiligo Cream in the EU


Boost your weekend mood with some good news:  

The European Medicines Agency expressed a positive opinion on Opzelura earlier this week. The green light opens the fast track for it to become the first ‘official’ vitiligo therapy in the EU. Incyte has been eagerly awaiting this approval ever since the it’s drug was registered by the US FDA in July 2022.  

Opzelura, a 1.5% ruxolitinib cream, is a sister medication to Incyte's JAK inhibitor, Jakafi. It is used to treat nonsegmental vitiligo in patients ages 12 and older, with primarily facial involvement. The cream is meant to be applied twice a day on affected areas of up to 10% of the body’s surface area, and patients may need to use it for up to 24 weeks in order to see the best results.


VYNE Therapeutics Inc. has recently announced positive results from the  Phase 1a/b clinical trial evaluating its novel BET inhibitor for vitiligo.

Prof. Mark Lebwohl, MD, shares updates on recent clinical breakthroughs and agents in the drug development pipeline. Read or watch interview with Dermatology Times at Winter Clinical Miami, held on February 20, 2023.


  • 🇰🇿 The World Vitiligo Day 2023 headquarters will be set in Almaty, Kazakhstan, under the leadership of Dr. Aliya Kassumkhanova. The preparations are in full swing, with incredible support from volunteers across the country. June 23-25, 2023. 
  • 🇷🇴 XII edition of Iasi Dermatological Spring will present the most  impactful topics in dermatology, - including vitiligo session by the VRF. April 27, 2023.


The first Public Service Announcement (PSA) for vitiligo went live across all major networks. Dr. Pearl Grimes emphasizes in a 1-minute video the importance of talking to a dermatologist about individual goals and management options. 

To date, this PSA has been picked up on 432 websites and 29,304 TV airings including top networks such as CNN, Fox News, CBS, MSNBC and more. Let's share this far and wide to hit over 800M views!

Wishing you a great weekend,

Yan Valle,
CEO VR Foundation




      FAQOther Questions

      • Which skin conditions can be mistaken for vitiligo?

        Vitiligo is a common skin condition with characteristic milky white patches of irregular shape. However, several other skin conditions exhibit similar symptoms that can lead to ...

      • What are risks of oral and topical corticosteroids?

        Corticosteroid drugs (like hydrocortisone, and others) are often used for treating vitiligo. By mimicing the effects of hormones your body produces naturally in your adrenal gla...

      • PTSD in Vitiligo?

        Vitiligo has long been associated with disease-related discrimination, social stigma, self-isolation, lower self-esteem, embarrassment, anxiety, and depression.  These chronic ...